Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 9% – What’s Next?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO)’s stock price shot up 9% during mid-day trading on Friday . The stock traded as high as $10.22 and last traded at $10.3250. 304,975 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 863,517 shares. The stock had previously closed at $9.47.

Wall Street Analysts Forecast Growth

A number of analysts have commented on LXEO shares. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Leerink Partners raised their price objective on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a report on Thursday, December 11th. Finally, Guggenheim started coverage on shares of Lexeo Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

Lexeo Therapeutics Stock Up 10.3%

The company has a market capitalization of $762.42 million, a P/E ratio of -3.87 and a beta of 1.75. The stock has a fifty day simple moving average of $9.48 and a 200-day simple moving average of $6.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.15. Analysts predict that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $34,758.72. Following the transaction, the insider owned 65,862 shares of the company’s stock, valued at $588,806.28. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider directly owned 73,261 shares of the company’s stock, valued at $654,953.34. The trade was a 4.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 24,646 shares of company stock valued at $221,037. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LXEO. Vanguard Personalized Indexing Management LLC lifted its holdings in Lexeo Therapeutics by 10.6% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock worth $110,000 after acquiring an additional 1,595 shares in the last quarter. Bank of America Corp DE raised its position in shares of Lexeo Therapeutics by 6.1% during the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares during the period. Intech Investment Management LLC grew its position in shares of Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after purchasing an additional 2,342 shares during the period. AXQ Capital LP raised its holdings in Lexeo Therapeutics by 19.6% during the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock worth $99,000 after buying an additional 2,446 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Lexeo Therapeutics by 42.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after buying an additional 2,799 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.